Clinical characteristics at start of mRNA vaccination against SARS-CoV-2 as well as timepoints of vaccination and tests in patients with CLL (n = 29) with a prior history of COVID-19 infection
| All patients . | . |
|---|---|
| Median age, y (range) | 65 (47-83) |
| Male/female | 20/9 |
| CLL treatment status | |
| Never treated | 72% (21/29) |
| Previously treated∗ | 21% (6/29) |
| Time (mo) since last treatment | 45.5 (15-70) |
| Ongoing therapy† | 7% (2/29) |
| Ongoing Ig supplement | 10% (3/29) |
| CLL stage (byRai) | |
| 0 | 83% (24/29) |
| I-II | 17% (5/29) |
| III-IV | 0% (0/29) |
| CLL remission status (byiwCLL) | |
| SD | 0% (0/29) |
| PD | 0% (0/29) |
| PR/CR | 34% (10/29) |
| Not applicable (never treated, early-stage) | 62% (18/29) |
| Not applicable (never treated, progressive disease) | 3% (1/29) |
| Time (mo) since COVID-19 diagnosis to vaccination, median (range) | |
| Dose 1 (n = 29) | 5.75 (1.75-13.75) |
| Interquartile range | 4.00-11.25 |
| Dose 3 (n = 27)‡ | 12 (7.75-19.75) |
| Interquartile range | 9.75-17.75 |
| Time (mo) since pretest to vaccination, median (range) | |
| Dose 1 (n = 28)‡ | 0.25 (0-4.25) |
| Interquartile range | 0-1.00 |
| Dose 3 (n = 25)‡ | 1.25 (0.25-2.75) |
| Interquartile range | 1.00-1.75 |
| Time (mo) since vaccination to test, median (range) | |
| Dose 2 (n = 25)‡ | 0.75 (0.25-2.5) |
| Interquartile range | 0.51-1.00 |
| Dose 3 (n = 27)‡ | 0.75 (0.5-1.5) |
| Interquartile range | 0.75-1.00 |
| Time (mo) between vaccine doses, median (range) | |
| Dose 1-2 (n = 29) | 1.5 (0.75-2.0) |
| Interquartile range | 1.37-1.50 |
| Dose 2-3 (n = 27) | 5 (2.75-8.25) |
| Interquartile range | 4.25-5.75 |
| Type of vaccine§ | |
| Dose 1 (n = 29) C = 25, S = 4 | |
| Dose 2 (n = 29) C = 25, S = 4 | |
| Dose 3 (n = 27) C = 25, S = 2 | |
| COVID-19 management‖ | |
| Hospital admission | 66% (19/29) |
| ICU admission | 7% (2/29) |
| Supplemental oxygen | 48% (14/29) |
| Corticosteroids | 31% (9/29) |
| Antiviral therapy (Remdesivir) | 14% (4/29) |
| Anticoagulation | 59% (17/29) |
| IvIg | 3% (1/29) |
| Convalescent plasma | 0% (0/29) |
| BTKi | 3% (1/29) |
| Tocilizumab | 0% (0/29) |
| Hydroxychloroquine | 3% (1/29) |
| All patients . | . |
|---|---|
| Median age, y (range) | 65 (47-83) |
| Male/female | 20/9 |
| CLL treatment status | |
| Never treated | 72% (21/29) |
| Previously treated∗ | 21% (6/29) |
| Time (mo) since last treatment | 45.5 (15-70) |
| Ongoing therapy† | 7% (2/29) |
| Ongoing Ig supplement | 10% (3/29) |
| CLL stage (byRai) | |
| 0 | 83% (24/29) |
| I-II | 17% (5/29) |
| III-IV | 0% (0/29) |
| CLL remission status (byiwCLL) | |
| SD | 0% (0/29) |
| PD | 0% (0/29) |
| PR/CR | 34% (10/29) |
| Not applicable (never treated, early-stage) | 62% (18/29) |
| Not applicable (never treated, progressive disease) | 3% (1/29) |
| Time (mo) since COVID-19 diagnosis to vaccination, median (range) | |
| Dose 1 (n = 29) | 5.75 (1.75-13.75) |
| Interquartile range | 4.00-11.25 |
| Dose 3 (n = 27)‡ | 12 (7.75-19.75) |
| Interquartile range | 9.75-17.75 |
| Time (mo) since pretest to vaccination, median (range) | |
| Dose 1 (n = 28)‡ | 0.25 (0-4.25) |
| Interquartile range | 0-1.00 |
| Dose 3 (n = 25)‡ | 1.25 (0.25-2.75) |
| Interquartile range | 1.00-1.75 |
| Time (mo) since vaccination to test, median (range) | |
| Dose 2 (n = 25)‡ | 0.75 (0.25-2.5) |
| Interquartile range | 0.51-1.00 |
| Dose 3 (n = 27)‡ | 0.75 (0.5-1.5) |
| Interquartile range | 0.75-1.00 |
| Time (mo) between vaccine doses, median (range) | |
| Dose 1-2 (n = 29) | 1.5 (0.75-2.0) |
| Interquartile range | 1.37-1.50 |
| Dose 2-3 (n = 27) | 5 (2.75-8.25) |
| Interquartile range | 4.25-5.75 |
| Type of vaccine§ | |
| Dose 1 (n = 29) C = 25, S = 4 | |
| Dose 2 (n = 29) C = 25, S = 4 | |
| Dose 3 (n = 27) C = 25, S = 2 | |
| COVID-19 management‖ | |
| Hospital admission | 66% (19/29) |
| ICU admission | 7% (2/29) |
| Supplemental oxygen | 48% (14/29) |
| Corticosteroids | 31% (9/29) |
| Antiviral therapy (Remdesivir) | 14% (4/29) |
| Anticoagulation | 59% (17/29) |
| IvIg | 3% (1/29) |
| Convalescent plasma | 0% (0/29) |
| BTKi | 3% (1/29) |
| Tocilizumab | 0% (0/29) |
| Hydroxychloroquine | 3% (1/29) |
C, Comirnaty; ICU, intensive care unit; IvIg, intravenous immunoglobulin; iwCLL, International Workshop on Chronic Lymphocytic Leukemia; PD, progressive disease; PR/CR, partial remission/complete remission; S, Spikevax; SD, stable disease.
With no current treatment. All with anti-CD20 monoclonal antibody–containing immunochemotherapy (bendamustine-rituximab/fludarabine-cyclophosphamide-rituximab) and all >12 months prior to vaccination.
Both with BTKi (ibrutinib). One was previously treated with immunochemotherapy >12 months ago and stopped ibrutinib therapy shortly after the second vaccine dose.
Number of patients at each time point is shown in Figure 1 and supplemental Figure 1.
Comirnaty (BNT162b2, Pfizer BioNTech), Spikevax (mRNA-1273, Moderna). Two patients did not receive dose 3.
March 2020 to March 2021.